Alaunos Q1 net loss $10M; debt-free after SVB loan prepayment; expects interim TCR-T data Q3

Alaunos Therapeutics, Inc.

2023-Q1 EPS reported -$0.04 vs consensus -$6.38 ▲ beat (+99.4%)

Net loss of $10.0M ($0.04/share) vs $9.8M ($0.05) in Q1 2022; R&D expenses up 17% to $6.5M.
Fully prepaid $11.0M SVB loan in May 2023; now debt-free; restricted cash of $13.9M released.
Interim clinical data from TCR-T Library Phase 1/2 trial expected Q3 2023; cryopreserved products manufactured.
Amended Precigen license: eliminated all royalties and milestones; retained exclusive rights to TCRs using Sleeping Beauty.
Cash $37.4M at March 31; expects cash into Q4 2023; 2023 operating outflows $35-40M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alaunos Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $10.0 million, EPS $(0.04) per share.

Period: the first quarter ended March 31, 2023
Net income: $10.0 million
EPS: $(0.04) per share
Result: reported results

Exact text from the filing

Net loss was $10.0 million, or $(0.04) per share, for the first quarter of 2023

View on SEC.gov

Browse all earnings releases →

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-140010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.